摘要
目的研究伊立替康联合卡培他滨对结直肠癌患者血清胰岛素样生长因子(IGF-Ⅱ)和转化生长因子α(TGF-α)水平的影响。方法入选结直肠癌患者98例,随机分为两组,治疗组51例,对照组47例。两组均给予卡培他滨1250mg·m^(-2),2次/d,连续给药2周;治疗组给予伊立替康180 mg·m^(-2)溶于250 m L生理盐水,静脉滴注90 min,d1;对照组给予奥沙利铂130 mg·m^(-2),静脉滴注120 min,d1。检测两组患者治疗前、治疗后1个月、治疗后6个月血清IGF-Ⅱ和TGF-α水平,并评价临床疗效。结果治疗后两组患者病情均有不同程度的改善,治疗组总有效率(90.20%)明显高于对照组(76.60%),差异有统计学意义(P<0.05)。治疗后1个月和治疗后6个月,两组患者血清IGF-Ⅱ、TGF-α表达水平均出现不同程度的下调,在治疗后6个月稍有回升,与治疗前比较,差异均有统计学意义(P<0.05)。治疗组血清IGF-Ⅱ、TGF-α表达水平下调作用更为明显,并且在治疗后6个月的回升程度仍低于对照组治疗后1个月的表达水平。结论伊立替康联合卡培他滨可有效降低结直肠癌患者血清IGF-Ⅱ和TGF-α表达水平,具有良好的临床疗效。
Objective To study the effects of irinotecan （CPT-II） combined with capecitabine （CAP） on the serum levels of insulin like growth factor II （IGF- II） and transforming growth factor a （TGF-α） of colorectal cancer patients. Methods In this study, 98 cases of color- ectal cancer patients were randomly divided into two groups, 51 cases in the treatment group and 47 cases in the control group. Both groups were given CAP at the dose of 1250 mg·m^-2 two times a day for a total of two weeks. The treatment group was added with the CPT-11 at the dose of 180 mg·m^-2 dissolved in 250 mL saline at dl, and the intravenous infusion time was 90 min. The control group was added with oxaliplatin at the dose of 130 mg·m^-2 at dl, and the intravenous infusion time was 120 min. The clinical effect of chemotherapy was evalu- ated by detecting the serum levels of IGF- II and TGF-α of all patients at the time of before treatment, one month after treatment and six months after treatment, respectively. Results After treatment, the patients＇ conditions in the two groups were improved in different degrees, but the overall effective rate of the treatment group （90.20%） was significantly higher than that of the control group （76.60%）, and the differ- ence was statistically significant （P 〈 0.05）. The serum levels of IGF- II and TGF-α both were decreased in different degrees at one month or six months after treatment, but with a slight rebound at six months after treatment, but there were still significant differences when compared with before treatment （P 〈 0.05）. The expression levels of IGF-II and TGF-α in the treatment group were reduced more obviously than in the control group. Furthermore, the levels of IGF- II and TGF-α at six months after treatment in the treatment group were still lower than those at one month after treatment in the control group. Conclusions CPT-11 combined with CAP could effectively reduce the serum expression levels of IGF- II and TGF-α in coiorectal cancer patients, and had a good clinical effect.
出处
《肿瘤药学》
CAS
2017年第2期224-229,共6页
Anti-Tumor Pharmacy
关键词
伊立替康
卡培他滨
晚期结直肠癌
胰岛素生长因子
转化生长因子Α
Irinotecan
Capecitabine
Advanced colorectal cancer
Insulin like growth factor
Transforming growth factor α
